Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The goal of the current study was to investigate the safety and determine the maximum
tolerated dose (MTD) of S-1 in combination with oxaliplatin and epirubicin in patients with
advanced or metastatic solid tumors.